Our results not only demonstrate a novel mechanism underlying regulation of the BCL6/BACH2 axis, but also indicate that this is one of the mechanisms underlying the therapeutic effect of CK2 inhibitors on high-risk ALL. This evidence concerns the gene BACH2 and acute lymphoblastic leukemia.